Beijing Yuanda Jiuhe Pharmaceutical

Beijing Yuanda Jiuhe Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company specializing in the respiratory and critical care therapeutic areas. Acquired by Grand Pharma (0512.HK) in 2015, the company serves as the group's core respiratory division. Its commercial portfolio includes Qienuo (Eucalyptus, Limonene and Pinene Enteric Capsules), Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray), and the asthma therapies Enerzair and Atectura (co-developed with Novartis). The company is also advancing a clinical pipeline of innovative therapies, notably STC3141, a novel small molecule extracellular histone neutralizer currently in Phase II clinical trials for sepsis, acute respiratory distress syndrome (ARDS), and severe COVID-19 pneumonia.